Micki Klearman
YOU?
Author Swipe
View article: Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial Open
Objective To assess the risk of major adverse cardiovascular events ( MACE ) in patients with rheumatoid arthritis ( RA ) treated with tocilizumab compared to those treated with the tumor necrosis factor inhibitor etanercept. Methods This …
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab Open
Objective This study was undertaken to evaluate glucocorticoid dosages and serologic findings in patients with giant cell arteritis ( GCA ) flares. Methods Patients with GCA were randomly assigned to receive double‐blind dosing with either…
View article: Trial of Tocilizumab in Giant-Cell Arteritis
Trial of Tocilizumab in Giant-Cell Arteritis Open
Tocilizumab, received weekly or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustained glucocorticoid-free remission in patients with g…
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study Open
Objective While tocilizumab (TCZ) is known to increase low‐density lipoprotein (LDL) cholesterol levels, it is unclear whether TCZ increases cardiovascular risk in patients with rheumatoid arthritis (RA). This study was undertaken to compa…